Certara's SWOT analysis: biosimulation firm's stock faces growth hurdles

Certara (CERT), a biosimulation software and AI-assisted drug development company, reported Q1 2025 revenue of $106.0 million, a 10% year-over-year increase, with software revenue up 18% and adjusted EBITDA up 20% to $34.8 million. The company is strategically positioned to benefit from the FDA's planned phase-out of animal testing with its non-animal navigator offerings, though declining net revenue retention and regulatory risks related to biosimulation data acceptance remain concerns. Analysts have price targets ranging from $13 to $18, with InvestingPro's Fair Value model suggesting the stock is currently undervalued.

Analysis

Certara, Inc. (NASDAQ:CERT) demonstrated robust financial health in its Q1 2025 report, with total revenue reaching $106.0 million, a 10% year-over-year increase that surpassed analyst consensus. This growth was underpinned by a notable 18% year-over-year rise in software segment revenue to $46.4 million (4% organic growth) and a 4% increase in services revenue to $59.6 million (3% organic growth). The company's adjusted EBITDA grew 20% year-over-year to $34.8 million, exceeding estimates and reflecting strong profitability alongside a healthy gross profit margin of 60.3% on trailing twelve-month revenue of $394.5 million. Strategically, Certara is well-positioned to capitalize on the FDA's plan to phase out animal testing through its "Non-Animal Navigator" solutions and is developing a comprehensive Cloud platform. However, the company faces headwinds, including a concerning sequential decline in net revenue retention since Q1 2024, potential risks from regulatory changes in biosimulation data acceptance, and weakness in its regulatory writing business, for which strategic alternatives are being explored. Valuation analysis indicates Certara trades at an EV/EBITDA multiple of 20.2x and approximately 14 times its estimated 2025 EBITDA, a discount compared to its peer Simulations Plus (SLP) at 19 times EBITDA. InvestingPro’s Fair Value model suggests the stock is currently undervalued, with analyst price targets ranging from $13 to $18, and Barclays recently reiterated an Overweight rating with a $14 target.

Key Decisions for Investors

• Given Certara's strong Q1 financial performance, strategic alignment with the shift away from animal testing, and potential undervaluation relative to peers and intrinsic value models, investors may find the current valuation attractive, while closely monitoring progress on its Cloud platform development.
• Investors should critically assess trends in Certara's net revenue retention, as continued declines could signal underlying challenges in customer satisfaction or competitive intensity, potentially impacting long-term growth projections and profitability.
• Closely monitor regulatory developments regarding the FDA's stance on animal testing alternatives and the acceptance of biosimulation data, as these are pivotal to Certara's growth thesis but also represent key risk factors.
• The ongoing strategic review of the regulatory writing business should be watched, as a potential divestiture or restructuring could streamline operations and allow management to focus on core, higher-growth software and AI-driven solutions.